Transcat, Inc. — Form 10-Q Summary
Reporting period: First quarter of fiscal 2021, ended June 27, 2020; comparable quarter ended June 29, 2019. The filing describes fiscal 2021, although the request metadata labels the period “2020 Q1.” Transcat provides calibration and laboratory instrument services and distributes test, measurement and control instruments.
Financial performance
| Metric | Q1 FY2021 | Q1 FY2020 | Change |
|---|---|---|---|
| Revenue | $38.9 million | $42.4 million | Down 8.2% |
| Gross profit / margin | $9.4 million / 24.2% | $10.1 million / 23.7% | Profit down 6.4%; margin up 50 bps |
| Operating income / margin | $1.0 million / 2.5% | $2.0 million / 4.6% | Income down 50.8% |
| Net income | $0.8 million | $1.7 million | Down 53.6% |
| Diluted EPS | $0.11 | $0.23 | Down $0.12 |
| Operating cash flow | $4.0 million | $0.9 million | Up $3.2 million |
| Capital expenditures | $1.3 million | $1.4 million | Down $0.2 million |
| Adjusted EBITDA | $3.5 million | $3.9 million | Down about 11.5% |
Service revenue rose 2.5% to $23.0 million, while Distribution sales fell 20.3% to $15.9 million. Service gross margin improved to 26.4% from 24.0%; Distribution gross margin declined to 21.0% from 23.4%. The filing attributes the overall revenue decline mainly to COVID-19-related demand weakness, particularly in Distribution. Service growth reflected stronger life-sciences demand and $1.1 million of revenue from pipettes.com, acquired in February 2020.
Balance sheet, debt and liquidity
- At June 27, 2020, cash was $0.4 million, current assets $45.2 million and current liabilities $17.9 million.
- Total debt was $28.5 million: $12.1 million on the term loan and $16.4 million outstanding on the revolving facility. The term loan bears fixed interest of 4.15%; revolving-facility rates ranged from 1.4% to 2.7% during the quarter.
- The amended revolving facility has a $40 million commitment and was extended to October 20, 2022. The company reported compliance with covenants and a 1.50 leverage ratio at quarter-end.
- Cash decreased $0.1 million during the quarter to $0.4 million. Operating cash flow was supported by a $2.9 million reduction in receivables; accounts payable fell $2.6 million. Financing cash use included $1.3 million of revolving-debt repayment, $0.5 million of term-loan repayment and $1.3 million of share withholding/repurchases.
- Days sales outstanding increased to 61 from 53 a year earlier. The allowance for doubtful accounts increased to $0.7 million from $0.5 million at fiscal year-end.
Material changes, outlook and risks
- Operating expenses increased 4.3% to $8.4 million, including approximately $0.4 million of severance expense and acquisition-related costs. Management said technology advancements enabled lower ongoing expenses but resulted in the one-time severance charge.
- Management reported Service demand strengthened through June and into July, but cautioned that renewed COVID-19 cases made the outlook uncertain. For Q2 FY2021, it expected modest Service revenue growth year over year, improved gross margin, Distribution relatively unchanged sequentially, and operating income of approximately $2 million—about $1 million higher sequentially.
- Fiscal 2021 expected effective tax rate was revised to 20%–21% from 24%–25%. Planned capital expenditures were $5.0–$5.5 million, within the amended facility’s $5.5 million fiscal-year cap.
- Management identified COVID-19, economic conditions, customer-sector demand, competition, cybersecurity and IT disruptions, employee retention, acquisitions and integration, indebtedness, vendor inventory and rebate programs, and foreign-exchange movements among risks.
- The company held a $4.0 million notional foreign-exchange forward contract at quarter-end, renewed in July. It had no hedging arrangements for revolving-facility interest-rate exposure; management estimated a 1% rate move would change annual interest expense by approximately $0.2 million at constant borrowing levels.
Investor verification points
- Verify the Q2 operating-income and segment outlook against subsequent results, particularly given the pandemic-related uncertainty.
- Track Distribution demand, vendor rebates/cooperative advertising, and whether the segment’s gross-margin decline persists.
- Assess receivable collections and credit quality in light of the higher DSO and allowance.
- Review debt covenant headroom, facility availability and the impact of interest-rate changes.
- Reconcile the MD&A’s Adjusted EBITDA narrative: its table reports $3.488 million versus $3.942 million, a decline, while nearby narrative appears to describe a different period and says EBITDA increased. The table also reports FY2021 Adjusted EBITDA margin of about 9.0%, while the narrative cites 9.3% for FY2020.